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OBJECTIVE: To investigate the role of oxidant/antioxidant status and protein oxidation in the development of age-
related macular degeneration.
METHOD: The activities of serum superoxide dismutase and glutathione peroxidase and the levels of serum
malondialdehyde, advanced oxidation protein products, glutathione and vitamin C were measured in 25 patients
with age-related macular degeneration and 25 control subjects without age-related macular degeneration.
RESULT: The malondialdehyde and advanced oxidation protein product levels in the serum were significantly higher
in the age-related macular degeneration patient group than in the control group (p,0.05). The superoxide
dismutase activity in the serum was significantly lower in the age-related macular degeneration patient group than
in the control group (p,0.05). The levels of vitamin C and glutathione and the activity of glutathione peroxidase in
the serum were unchanged between groups (p.0.05).
CONCLUSION: The results of the present study suggest that decreased effectiveness of the antioxidant defense
system and increased oxidative stress may play a role in the pathogenesis of age-related macular degeneration.
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INTRODUCTION
Age-related macular degeneration (AMD) is the leading
cause of irreversible visual impairment and blindness
among people aged 60 years and older.1 Although the
disease presents a serious social and economic problem, its
pathogenesis and etiology are still unclear.2,3 Based on the
disease’s clinical and pathological features, there are two
subtypes of late AMD: atrophic (dry) and neovascular (wet),
both of which can lead to significant visual loss.4
Over the past decade, the body of literature regarding
the modifiable factors associated with AMD has grown
considerably and includes cigarette smoking, age,5 nutri-
tional factors,6-8 obesity9 and insufficient antioxidants in
the diet.10
The eye is an exceptional organ because of its continuous
exposure to environmental chemicals, radiation, and atmo-
spheric oxygen.11 These oxidative stresses have been
implicated in the possible pathophysiology of various
ocular diseases, such as AMD, cataracts, glaucoma, uveitis,
and pseudoexfoliation syndrome. Reactive oxygen species
(ROS) are involved in this process. Several ocular degen-
erative disorders have been studied, and the presence of
oxidative stress has been demonstrated through markers of
lipid peroxidation, the activity of antioxidant enzymes, and
the levels of low-molecular-weight antioxidants.12
Non-enzymatic lipid peroxidation is an example of a free
radical-associated process through which oxidative stress
promotes cellular damage. Serum malondialdehyde (MDA)
is the end product of the primary reactions that lead to the
significant oxidation of such polyunsaturated fatty acids in
cellular membranes and, thus, serves as a reliable marker of
oxidative stress.13 Protein oxidation is currently considered
to be an important factor in a variety of diseases, such as
Alzheimer’s and Parkinson’s diseases, cancer, hypertension,
cardiovascular disease, diabetes, ischemia-reperfusion
injury and aging.14,15
Advanced oxidation protein products (AOPP) are
described as dityrosines that contain cross-linked protein
products. Importantly, this definition excludes protein
aggregates that form as a result of disulfide links following
low-level oxidative stress. Therefore, the presence of AOPP
may be a better and more accurate marker of oxidative
stress than lipid peroxidation products.16
Endogenous antioxidants, including such non-enzymatic
scavengers as glutathione (GSH) and such antioxidant
enzymes as superoxide dismutase (SOD), glutathione
peroxidase (GPx), and catalase (CAT), are the first lines of
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defense against oxidative stress and act by scavenging
potentially damaging free radical moieties.17
Ascorbate (vitamin C) is the most effective aqueous-phase
antioxidant found in human blood. Increasing evidence
suggests that, within the aqueous phase, vitamin C plays a
vital role in the antioxidant defense mechanism of the eye,
protecting ocular tissues against photooxidative damage by
acting as a free radical scavenger.18
Determining the level of oxidative stress encountered by the
human eye has not yet been attempted in clinical diagnoses
and/or treatment.19 The aim of the present study was to
investigate the role of antioxidants and protein and lipid
peroxidation in the development of AMD. Therefore, we
measured the activities of the SOD and GPx enzymes and the
serum levels of MDA, AOPP, GSH and vitamin C in patients
with AMD and in control subjects not exhibiting AMD.
MATERIALS AND METHODS
This study included 15 men and 10 women (mean
age¡SD; 65.16¡13.96 years) with AMD and choroidal
neovascular (CNV) membrane, which is secondary to AMD.
The control group included 15 men and 10 women (mean
age¡SD; 65.72¡12.62 years). No statistically significant
differences between the groups were observed in terms of
age and sex. Patients with other ophthalmic conditions (e.g.,
glaucoma, uveitis, pseudoexfoliation syndrome, other pro-
gressive retinal diseases) and systemic diseases (e.g.,
diabetes, arthritis, coronary arterial disease, peripheral
vascular disease) were excluded.
All subjects, both in the control group and the patient
group, completed a questionnaire confirming the following
information: age, gender, non-smoker status, non-consump-
tion of supplements, such as vitamins and/or antioxidants.
All patients with AMD were first tested to ensure that they
did not ingest antioxidant vitamins and minerals. After
obtaining blood samples from the patients, we initiated anti-
vascular endothelial growth factor therapy.
All patients underwent a comprehensive ophthalmic
examination. CNV was diagnosed by slit-lamp biomicro-
scopy of the fundi, color fundus photographs, fundus
fluorescein angiographies, and optical coherence tomogra-
phies. The control subjects exhibited entirely normal
ophthalmic conditions. For this study, the rules of the
Human Ethics Committee were followed. Blood samples,
which were drawn from patients and control subjects after
an overnight fast and before the operation, were centrifuged
at 2,0006g for 10 min at 4 C˚. Serum samples were stored at
270 C˚ for further analysis.
AOPP levels were measured by a spectrophotometric method
(Shimadzu UV 1601 spectrophotometer, Shimadzu, Tokyo,
Japan) in the presence of potassium iodide at 340 nm16 and
using chloramine-T solutions for calibration. AOPP levels were
expressed in micromoles of chloramine-T equivalents per liter.
Lipid peroxidation was estimated using the thiobarbituric
acid-reactive substances (TBARS) test, as described pre-
viously.20 Briefly, the formation of TBARS was quantitated
using 1,1,3,3-tetraethoxypropane as a standard, and the
absorbances of the TBARS were read at 532 nm using a
Shimadzu UV 1601 spectrophotometer (Tokyo, Japan).
The GSH levels were determined as total sulfhydryl
group (R-SH).21 A 0.5 ml aliquot of each sample was mixed
with 1 ml of a solution containing 100 mM Tris-HCl pH 8.2,
1% sodium dodecyl sulfate (SDS) and 2 mM EDTA. The
mixture was incubated for 5 min at 25 C˚ and centrifuged to
remove any precipitate. Next, 5,5-dithiobis (2-nitrobenzoic
acid)/DTNB 0.3 mM was added to each reaction volume,
and the reaction was incubated for 15 min at 37 C˚. The
absorbance of each sample was determined at 412 nm. The
R-SH levels were calculated assuming a molar extinction
coefficient of 13,000 mol-1 cm-1 at 412 nm.
The SOD activity was measured by inhibiting this activity
through nitroblue tetrazolium (NBT) reduction. Xanthine-
xanthine oxidase was used as a superoxide generator, and
one IU was defined as the quantity of SOD required to
produce a 50% inhibition.22
The level of GPx activity was determined spectrophotome-
trically as described in the literature.23 The reaction mixture,
containing a 50 mM phosphate buffer pH 7.4, 7.7 units of GSH
reductase, 5 mM GSH, and crude extract, was preincubated for
5 min at 37 C˚. Next, 20 ml of a nicotinamide adenine
dinucleotide phosphate solution in the reduced form
(NADPH) (0.3 mM) was added, and the hydroperoxide-
independent consumption of NADPH was monitored for
approximately 5 min. The overall reaction was started by
adding 20ml of prewarmed hydroperoxide solution (0.025 mM),
and the reduction in absorption at 340 nm was monitored.
The level of total ascorbate was determined by the modified
Roe and Kuether method.24 Serum samples were added to a
trichloroacetic acid solution and centrifuged at 3,0006g for
10 min. Next, a 2,4-dinitropheyhydrazine(DNPH)-thiourea-
copper sulfate reagent was added to the serum sample tubes.
The contents of each tube were mixed, capped with parafilm,
and placed in a water bath at 37 C˚ for 4 h, after which the tubes
were removed and cooled in ice water. An ice-cold 65%
sulfuric acid solution was added to each tube, and the sample
was mixed thoroughly. The mixture was allowed to stand at
room temperature for 30 min, and the absorbance of each tube
was read in a Shimadzu UV 1601 model spectrophotometer at
515 and 520 nm. The lower limit of detection for vitamin C was
0.05 mmol/L.
Statistical Analysis. Data are presented as the mean¡SD.
Statistical analyses were conducted by Kruskal Wallis test and
Mann-WhitneyU-test (SPSS for Windows 11.5; SPSS, Chicago,
IL, USA). A value of p,0.05 was defined as significant.
RESULTS
This study included a total of 50 subjects who were
equally divided among two groups, an AMD group and a
control group. The mean age was 65.16¡13.96 years (40-89
years) (for 15 men and 10 women) in the AMD group and
65.72¡12.62 years (36-89 years) (for 15 men and 10 women)
in the control group. All of the groups were matched for age
and gender, and no statistically significant differences were
observed. The levels of MDA and AOPP in the serum were
significantly higher in the AMD patient group than in the
control group (p,0.05) (Table 1). Furthermore, the level of
SOD activity in the serum was significantly lower in the
AMD patient group than in the control group (p,0.05)
(Table 1). In addition, the levels of vitamin C and GSH and
the activities of GPx in the serum were unchanged between
the two groups (p.0.05) (Table 1).
DISCUSSION
AMD is a complex, multifactorial disease of aging for
which several theories of pathogenesis have been proposed,
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including oxidative damage25 and ocular perfusion abnorm-
alities.26
Oxidative stress may cause injury to the retinal pigment
epithelium (RPE), the Bruch’s membrane, and the choroid,
which are layers in the eye involved in the pathophysiology
of AMD.27-31
Liang et al.32 demonstrated that human RPE cells exposed
to oxidative stress or rod outer segments exhibited damage
primarily to mitochondrial (mt) DNA and that damaged
mtDNA was not efficiently repaired.
The retina is particularly susceptible to oxidative stress
due to its high concentration of oxygen, its high proportion
of polyunsaturated fatty acids, and its exposure to visible
light.33 Prior reports have suggested that the retina is
susceptible to lipid peroxidation34,35 and that this suscept-
ibility also increases with aging in the macular region.35
Previous studies demonstrated that the plasma MDA
levels were higher in an AMD patient group than in a
control group.36,37 In the present study, we found that the
serum MDA levels were significantly higher in the AMD
patient group than in the control group, in agreement with a
previous study.38
Protein oxidation is also a useful marker for the
evaluation of oxidative stress in vivo. Many different types
of protein oxidative modifications can be induced by free
radicals. A prior study demonstrated that the levels of
protein carbonyl groups in the serum were higher in the
AMD patient group than in the control group.38
AOPP measurements reflect the generation of free radicals
and the degree of protein oxidation.16,39 In the present study,
we found that the levels of AOPP in the serum were
significantly higher in the AMD patient group than in the
control group. Therefore, this study demonstrated that
protein oxidation, a useful oxidative stress marker, is
upregulated in AMD, suggesting increased oxidative stress.
Antioxidant enzymes are a primary defense system that
protects biological macromolecules from oxidative damage.
SOD, CAT and GPx are antioxidant enzymes that form part
of the complex system that protects the retina from
oxidative damage, and all three of these enzymes are found
in the photoreceptors and the RPE.40 SOD is a key
antioxidant enzyme involved in the metabolism of oxygen
free radicals.41 A previous report suggested that the
activities of SOD in plasma and erythrocytes were lower
in the AMD patient group than in the control group.37 In the
present study, we found that the activities of SOD in the
serum were significantly lower in the AMD patient group
than in the control group.
GSH is a major non-enzymatic antioxidant that is effective
in protecting cells against to reactive oxygen products and
toxins. A high concentration of GSH is present in most
living cells, and GSH is involved in the responses to various
stresses. The redox condition of cells is associated with their
degree of protection by GSH in the reduced state.42
A prior study demonstrated that the plasma GSH levels
were lower in an AMD patient group than in a control
group.43 In the present study, however, we determined that
the serum GSH levels were unchanged between our groups.
GPx uses GSH as an electron donor to reduce organic
hydroperoxides. GPx is found in the human retina and is
dependent on selenium as a cofactor. Extracellular GPx is
found in the retina, ciliary epithelium, and aqueous humor,
and GPx may act as an extracellular antioxidant.33
A previous study demonstrated that the activities of GPx
in the plasma and erythrocytes were lower in an AMD
patient group than in a control group.37,43 In the present
study, the GPx activities in the serum were unchanged
between groups.
Vitamin C is the second major water-soluble antioxidant.
An important function of vitamin C is protecting the lens by
means of direct absorption of ultraviolet radiation by
aqueous vitamin C.44
A prior study demonstrated that the low levels of vitamin
C in the plasma were associated with an increased risk of
AMD but that high levels were not protective.44 In the
present study, the serum vitamin C levels were unchanged
between groups.
Much of the research into the relationship between
oxidative stress and AMD has focused on the antioxidant
status of subjects with and without the disease, and the
limitations of these studies are worth noting.
Deficiencies in antioxidant enzymes may be related to the
development of disease. Because the retina suffers oxidative
damage, antioxidant nutrients are thought to be protective
of the retina through their function as antioxidants.
The results of the present study suggest that reductions in
the antioxidant defense system and increased oxidative
stress may play a role in the pathogenesis of AMD.
In conclusion, increased oxidative stress, which causes
oxidative damage to lipids and proteins and decreases
antioxidant capacity, may lead to irreversible damage in the
form of AMD. Further studies that analyze samples
obtained both from the serum and the aqueous humor are
required to confirm our findings.
ACKNOWLEDGMENTS
None of the authors has a proprietary or financial interest in any material
or method mentioned in this manuscript.
REFERENCES
1. Seddon JM, George S, Rosner B, Rifai N. Progression of age-related
macular degeneration: prospective assessment of C-reactive protein,
interleukin 6 and, and other cardiovascular biomarkers. Arch
Ophthalmol. 2005;123:774-82, doi: 10.1001/archopht.123.6.774.
2. Drobek-Slowik M, Karczewicz D, Safranow K. The potential role of
oxidative stress in the pathogenesis of the age-related macular
degeneration (AMD). Postepy Hig Med Dosw. 2007;61:28-37.
3. Ding X, Patel M, Chan CC. Molecular pathology of age-related macular
degeneration. Prog Retin Eye Res. 2009;28:1-18, doi: 10.1016/j.preteyeres.
2008.10.001.
4. Tsai YY, Lin JM, Wan L, Lin HJ, Tsai Y, Lee CC, et al. Interleukin gene
polymorphisms in age-related macular degeneration. Invest Ophthalmol
Vis Sci. 2008;49:693-8, doi: 10.1167/iovs.07-0125.
5. Smith W, Assink J, Klein R, Mitchell P, Klacer CC, Klein BE, et al. Risk
factors for age-related macular degeneration: pooled findings from three
continents. Ophthalmology. 2001;108:697-704, doi: 10.1016/S0161-
6420(00)00580-7.
Table 1 - Oxidation markers are down-regulated in AMD
patients and Control Subjects (mean¡SD).
AMD group (n=25) Control group (n =25)
SOD (U/mL) 4.99¡3.09* 9.91¡4.42
GPx (U/mL) 12.97¡11.23 15.79¡11.20
MDA (nmole/L) 6.39¡1.80* 4.90¡1.97
AOPP (mmole/L) 251.89¡69.58* 181.43¡43.11
GSH (nmole/mL) 310.05¡102.51 331.03¡129.45
Vitamin C (mmole/L) 2.54¡1.50 3.14¡1.54
*p,0.05, as compared with the control group.
CLINICS 2011;66(5):743-746 Oxidation and Antioxidants in AMD
Yildirim Z et al.
745
6. Seddon JM, Cote J, Rosner B. Progression of age-related macular
degeneration: association with dietary fat, transunsaturated fat, nuts,
and fish intake. Arch Ophthalmol. 2003;121:1728-37, doi: 10.1001/
archopht.121.12.1728.
7. Seddon JM, Rosner B, Sperduto RD, Yannuzzi L, Haller JA, Blair NP,
et al. Dietary fat and risk for advanced age-related macular degeneration.
Arch Ophthalmol. 2001;119:1191-9.
8. Cho E, Hung S, Willett W, Spiegelman D, Rimm EB, Seddon JM, et al.
Prospective study of dietary fat and the risk of age-related macular
degeneration. Am J Clin Nutr. 2001;73:209-8.
9. Seddon JM, Cote J, Davis N, Rosner B. Progression of age-related
macular degeneration: association with body mass index, waist
circumference, and waist-hip ratio. Arch Ophthalmol. 2003;21:785-92,
doi: 10.1001/archopht.121.6.785.
10. Seddon JM, Ajani UA, Sperduto RD, Dietary carotenoids, vitamins A, C,
and E, and advanced age-related macular degeneration. Eye disease
Case-Control Study Group. JAMA. 1994;272:1413-20, doi: 10.1001/jama.
272.18.1413.
11. Ohia SE, Opere CA, Leday AM. Pharmacological consequences of
oxidative stress in ocular tissues. Mutat Res. 2005;579:22-36.
12. Halliwell B, Gutteridge J. Free radicals in biology and medicine. 3rd ed.
New York:Oxford University Press Inc, 1989:1-35.
13. Irmak MK, Fadillioglu E, Sogut S, Erdogan H, Gulec M, Ozer M, et al.
Effects of caffeic acid phenethyl ester and alpha-tocopherol on reperfu-
sion injury in rat brain. Cell Biochem Funct. 2003;21:283-9, doi: 10.1002/
cbf.1024.
14. Touyz RM. Reactive oxygen species and angiotensin II signaling in
vascular cells-implications in cardiovascular disease. Braz J Med Biol
Res. 2004;37:1263-73, doi: 10.1590/S0100-879X2004000800018.
15. Olivares-Corichi IM, Ceballos G, Ortega-Camarillo C, Guzman-Grenfell
AM, Hicks JJ. Reactive oxygen species (ROS) induce chemical and
structural changes on human insulin in vitro, including alterations in its
immunoreactivity. Front Biosci. 2005;10:834-43.
16. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T,
Nguyen AT, Zingraff J, et al. Advanced oxidation protein products as a
novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304-13,
doi: 10.1038/ki.1996.186.
17. Harman D. Free radical theory of aging: An update: Increasing the
functional life span. Ann N Y Acad Sci. 2006;1067:10-21, doi: 10.1196/
annals.1354.003.
18. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in
adults: scientific review. JAMA. 2002;287:3116-26, doi: 10.1001/jama.287.
23.3116.
19. Pryor WA, Godber SS. Noninvasive measures of oxidative stress status
in humans. Free Radic Biol Med. 1991;10:177-84, doi: 10.1016/0891-
5849(91)90073-C.
20. Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in
maternal and cord blood and protective mechanism against activated-
oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372-6.
21. Kurtel H, Granger DN, Tso P, Grisham MB. Vulnerability of intestinal
interstitial fluid to oxidant stress. Am J Physiol. 1992;263:G573-78.
22. Sun Y, Oberley LW, Li Y. A simple method for clinical assay of
superoxide dismutase. Clin Chem. 1988;34:497–500.
23. Paglia DE, Valentine WN. Studies on the quantitative and qualitative
characterization of erytrocyte glutathione peroxidase. J Lab Clin Med.
1967;70:158-69.
24. Mapson LW. The estimation of dehydro-L-ascorbic acid when present in
low concentration in tissues, by the Roe and Kuether procedure.
Ann N Y Acad Sci. 1961; 92:284-5, doi: 10.1111/j.1749-6632.1961.
tb46127.x.
25. Cai J, Nelson KC, Wu M, Sternberg PJr, Jones DP. Oxidative damage and
protection of the RPE. Prog Retin Eye Res. 2000;19:205-21, doi: 10.1016/
S1350-9462(99)00009-9.
26. Harris A, Chung HS, Ciulla TA, Kagemann L. Progress in measurement
of ocular blood flow and relevance to our understanding of glaucoma
and age-related macular degeneration. Prog Retin Eye Res. 1999;18:669-
87, doi: 10.1016/S1350-9462(98)00037-8.
27. Johnson LV, Ozaki S, Staples MK, Erickson PA, Anderson DH. A
potential role for immune complex pathogenesis in drusen formation.
Exp Eye Res. 2000;70:441-9, doi: 10.1006/exer.1999.0798.
28. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated
with aging and age-related macular degeneration contain proteins
common to extracellular deposits associated with atherosclerosis,
elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000;14:835-
46.
29. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement
activation and inflammatory processes in drusen formation and age
related macular degeneration. Exp Eye Res. 2001;73:887-96, doi: 10.1006/
exer.2001.1094.
30. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH,
Mullins RF. An integrated hypothesis that considers drusen as
biomarkers of immune-mediated processes at the RPE-Brunch’s mem-
brane interface in aging and age-related macular degeneration. Prog
Retin Eye Res. 2001;20:705-32, doi: 10.1016/S1350-9462(01)00010-6.
31. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role of for local
inflammation in the formation of drusen in the aging eye.
Am J Ophthalmol. 2002;134:411-31, doi: 10.1016/S0002-9394(02)01624-0.
32. Liang FQ, Godley BF. Oxidative stress-induced mitochondrial DNA
damage in human retinal pigment epithelial cells: a possible mechanism
RPE aging and age-related macular degeneration. Exp Eye Res.
2003;76:397-403, doi: 10.1016/S0014-4835(03)00023-X.
33. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative
stress in the pathogenesis of age-related macular degeneration. Surv
Ophthalmol. 2000;45:115-34, doi: 10.1016/S0039-6257(00)00140-5.
34. Ito T, Nakano M, Yamamoto Y, Hiramitsu T, Mizuno Y. Hemoglobin-
induced lipid peroxidation in the retina: a possible mechanism for
macular degeneration. Arch Biochem Biophys. 1995;316:864-72, doi: 10.
1006/abbi.1995.1116.
35. De La Paz MA, Anderson RE. Lipid peroxidation in rod outer segments.
Role of hydroxyl radical and lipid hydroperoxides. Invest Ophthalmol
Vis Sci. 1992;33:2091-6.
36. Totan Y, C¸ekic¸ O, Borazan M, Uz E, So¨g˘u¨t S, Akyol O. Plasma
malondialdehyde and nitric oxide levels in age related macular
degeneration. Br J Ophthalmol. 2001;85:1426-8, doi: 10.1136/bjo.85.12.
1426.
37. Evereklioglu C, Er H, Doganay S, Cekmen M, Turkoz Y, Otlu B, Ozerol E.
Nitric oxide and lipid peroxidation are increased and associated with
decreased antioxidant enzyme activities in patients with age-related
macular degeneration. Doc Ophthalmol. 2003;106:129-36, doi: 10.1023/
A:1022512402811.
38. Totan Y, Yag˘ci R, Bardak Y, Ozyurt H, Kendir F, YI˙lmaz G, Sahin S, Sahin
Tıg˘ U. Oxidative macromolecular damage in age-related macular
degeneration. Curr Eye Res. 2009;34:1089-93, doi: 10.3109/
02713680903353772.
39. Alderman CJ, Shah S, Foreman JC, Chain BM, Katz DR. The role of
advanced oxidation protein products in regulation of dendritic cell
function. Free Radic Bio Med. 2002;32:377-85, doi: 10.1016/S0891-
5849(01)00735-3.
40. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative
stress in the pathogenesis of age-related macular degeneration. Surv
Ophthalmol. 2000;45:115-34, doi: 10.1016/S0039-6257(00)00140-5.
41. Enghild JJ, Thogersen IB, Oury TD, Valnickova Z, Hojrup P, Crapo JD.
The heparin-binding domain of extracellular superoxide dismutase is
proteolytically processed intracellularly during biosynthesis. J Biol
Chem. 1999;274:14818-22, doi: 10.1074/jbc.274.21.14818.
42. Penninckx M. A short review on the role of glutathione in the response of
yeasts to nutritional, environmental, and oxidative stresses. Enzyme
Microb Technol. 2000;26:737-42, doi: 10.1016/S0141-0229(00)00165-4.
43. Samiec PS, Drews-Botsch C, Flagg EW, Kurtz JC, Sternberg PJr, Reed RL,
Johns DP. Glutathione in human plasma decline: in association with
aging, age-related macular degeneration, and diabetes. Free Radic Biol
Med. 1998;24:699-704, doi: 10.1016/S0891-5849(97)00286-4.
44. Antioxidant status and neovascular age-related macular degeneration.
Eye Disease Case-Control Study Group. ch Ophthalmol. 1993;111:104-
9Erratum in: Arch Ophthalmol 1993 Sep;111(9):1228, 1993
Oct;111(10):1366. Arch Ophthalmol 1993 Nov;111(11):1499.
Oxidation and Antioxidants in AMD
Yildirim Z et al.
CLINICS 2011;66(5):743-746
746
